Skip to main content
Equibles

MEDANTA · Global Health Limited

Use MEDANTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MEDANTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,453.55 INR +13.90 (+0.97%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 6880 Avg daily vol (3M) 48.61K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close1,453.55 INR Open1,435.05 INR Day1,435.00–1,463.00 INR 52W close961.75–1,512.60 INR Avg vol 30d61K Last earningsNov 4, 2026 DataNov 2022–Nov 2026

Latest documents

2026
Nov 4
Earnings call
Q2 revenue rises 34%, operating EBITDA grows 60%

Global Health Limited reported Q2 FY27 revenue from operations of INR 14,690 million, up 34% year-on-year, and operating EBITDA of INR 3,701 million, up 60%, with a 25.2% margin. Noida reached EBITDA breakeven, while a 500-bed Ghaziabad hospital was approved.

5 source passages
Global Health Limited – Medanta Consolidated revenue from operations for the quarter was INR 14,690 million, representing a healthy growth of 34% year-on-year. Operating EBITDA grew 60% year-on-year to INR 3,701 million, with improved margins of 25.2% in Q2 FY27 compared to 21% in Q2 FY26. Medanta Noida achieved EBITDA breakeven in Q2 FY27, posting revenue from operations of INR 1,059 million and operating EBITDA of INR 86 million for the quarter. Let me now brief you on our new Ghaziabad hospital project. Yesterday, our Board has approved a 500-bed hospital project with a total capex of approximately INR 1,000 crores. Open the document at this passage
All documents

Quarterly results

Revenue Net income Net loss
▲13.3% 9.43B INR 1.43B INR '25 Q3 ▲15.2% 9.31B INR 1.01B INR '25 Q4 ▲19.7% 10.31B INR 1.59B INR '26 Q1 ▲14.9% 10.99B INR 1.58B INR '26 Q2 ▲18.8% 11.21B INR 950.22M INR '26 Q3 ▲24.5% 11.59B INR 1.44B INR '26 Q4 ▲26.5% 13.04B INR 1.59B INR '27 Q1 LATEST ▲33.6% 14.69B INR 0 INR '27 Q2

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 961.75 INR Now 1,453.55 INR · 89% Range high 1,512.60 INR
vs 200-day avg +16% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XBOM:MEDANTA +4.8% +13.8% +17.3% +14.5% +22.6%

Exchange listing

Market
XBOM
Ticker
MEDANTA
ISIN
INE474Q01031
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.medanta.org/
Investor relations
https://www.medanta.org/investor_relations/annual-reports/esop-disclosures

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

Ex-dividend dateAmount per share
2026-08-14 0.50 INR
2025-08-22 0.50 INR

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-04 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-07-31 Transcript
    Earnings Call for the Quarter Ended June 30, 2026
  • Earnings call · Q4 2026 2026-05-15 Transcript
    Earnings Call for the Quarter Ended March 31, 2026